Adjuvant Manufacturers and Companies

Adjuvants are broadly classified into three types: (1) Mineral salts, such as alum, which depot antigens and activate innate immunity; (2) Emulsion-based adjuvants, such as MF59 and AS03, which stimulate cytokine production; and (3) Saponin-based adjuvants, such as QS-21 and Matrix-M, which simultaneously promote antibody production and cellular (T-cell) immunity, making them particularly effective for intracellular pathogens and cancer vaccines.

QS-21 is an acylated triterpene glycoside saponin (molecular weight 1990 Da) extracted from the bark of the Chilean soapbark tree, Quillaja saponaria Molina. It is purified via reverse-phase HPLC to pharmaceutical grade. Desert King International produces it under GMP and EXCiPACT-certified conditions at facilities in Chile, Mexico, and Italy, with a current capacity of 5 kg annually—supporting 200–400 million human doses.

QS-21 is a key component in 5 globally approved vaccines: Shingrix (shingles, >95% efficacy), Mosquirix/RTS,S and R21/Matrix-M (malaria), Arexvy (RSV), and select COVID-19 vaccine formulations. It functions within composite adjuvant systems including AS01, AS02, ALFQ, and Matrix-M, enhancing both humoral and cellular immune responses.

Yes. Desert King International offers veterinary-specific adjuvant products derived from Quillaja saponaria, including QA-21 (lyophilized powder), Vet-sap (90% powder), and Ultra (65–70% powder). These are applied in poultry, swine, aquaculture (tilapia, shrimp, salmon), and ruminant health programs, improving disease resistance, growth performance, and immune modulation comparable to antibiotic growth promoters.

QS-21 from Desert King International is GMP-certified, IPEC GMP-certified, and EXCiPACT-certified—the only global Quillaja supplier with EXCiPACT status. Raw material sourcing is FSC (Forest Stewardship Council) certified. VuRoyal Pharmaceutical is an FDA-registered, Massachusetts-approved wholesaler compliant with USP guidelines, Title 21 CFR, PDMA, and DSCSA regulations, ensuring end-to-end supply chain integrity.

QS-21 is currently in Phase I–III clinical trials for over 20 vaccine candidates, including HIV, multiple cancer types, herpes, Alzheimer's disease, pneumococcal infection, hepatitis B, Clostridium, and anthrax. Its ability to simultaneously stimulate antibody production and cellular immunity makes it a lead adjuvant candidate for complex disease targets requiring robust T-cell responses.